Listar por autor "Guerrero, Miguel"
Mostrando ítems 1-12 de 12
-
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFN beta in Multiple Sclerosis Patients According to the Therapeutic Response to IFN beta
Hurtado-Guerrero, Isaac; Pinto-Medel, María-Jesús; Urbaneja, Patricia; Rodríguez-Bada, José Luis; León, Antonio; Guerrero, Miguel; Fernández-Fernández, Óscar; Leyva-Fernández, Laura
; Oliver-Martos, Begoña[et al.] (Public Library of Science, 2017)
Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable ... -
Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Pinto-Medel, Maria Jesús; Mayorga Mayorga, Cristobalina; García-León, Juan Antonio; Maldonado-Sanchez, Rafael; Suardíaz García, Margarita; Guerrero, Miguel; Luque, Gloria; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (Elsevier, 2011)
IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged ... -
HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)
Fernández Fernández, Óscar; Rodríguez-Antigüedad, Alfredo; Pinto-Medel, María Jesús; Mendibe, Mari Mar; Acosta, Nestor; Oliver-Martos, Begoña; Guerrero, Miguel; Papais-Alvarenga, Marcos; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (Springer, 2009)
Genetic susceptibility to multiple sclerosis (MS) is associated with genes of the major histocompatibility complex, particularly with the HLA DRB1*1501-DQA1*0102-DQB1*0602 haplotype in Caucasians. To investigate the ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
Leyva-Fernández, Laura; Fernández Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández Sánchez, Victoria Eugenia; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María-Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNbeta treatment response in a group of 147 patients ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández, Victoria E.; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005-04-22)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNβ treatment response in a group of 147 patients and ... -
IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).
Alcina, Antonio; Fedetz, María; Ndagire, Dorothy; Fernández Fernández, Óscar; Leyva-Fernández, Laura; Guerrero, Miguel; Abad-Grau, María del Mar; Arnal, Carmen; Delgado, Concepción; Lucas, Miguel; Izquierdo, Guillermo; Matesanz, Fuencisla[et al.] (Public Library of Science, 2009)
Background:IL-2 receptor (IL2R) alpha is the specific component of the high affinity IL2R system involved in the immune response and in the control of autoimmunity. Methods and Results: Here we perform a replication and ... -
Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations
Kristjansdottir, G; Sandling, JK; Bonetti, A; Roos, IM; Milani, L; Wang, C; Gustafsdottir, SM; Sigurdsson, S; Lundmark, A; Tienari, PJ; Koivisto, K; Elovaara, I; Pirttilä, T; Reunanen, M; Peltonen, L; Saarela, J; Hillert, J; Olsson, T; Landegren, U; Alcina, Antonio; Fernández Fernández, Óscar; Leyva-Fernández, Laura; Guerrero, Miguel; Lucas, Miguel; Izquierdo, Guillermo; Matesanz, Fuencisla; Syvänen, A-C[et al.] (BMJ, 2008)
Background: IRF5 is a transcription factor involved both in the type I interferon and the toll-like receptor signalling pathways. Previously, IRF5 has been found to be associated with systemic lupus erythematosus, rheumatoid ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients.
Fernández Fernández, Óscar; Mayorga Mayorga, Cristobalina; Luque, Gloria; Guerrero, Miguel; Guerrero, Rocío; Leyva-Fernández, Laura; León-Martín, Antonio; Blanca, Miguel[et al.] (Springer Nature, 2001)
Interferon (IFN)-β is generally considered an effective treatment for multiple sclerosis (MS); however, some patients do not respond to this therapy, possibly due to the production of neutralising antibodies (NAB) which ... -
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández Fernández, Óscar; Papais Alvarenga, Marcos; Guerrero, Miguel; León, Antonio; Alonso, Ana; López-Madrona, Jose Carlos; Leyva-Fernández, Laura; Oliver-Martos, Begoña; De Ramón, Enrique; Luque, Gloria; Fernández, Victoria[et al.] (Sage Publications, 2010-11-18)
Background: Little is known about how the level of disability at the start of treatment with natalizumab affects its efficacy. Objectives: The aim of this study was to investigate the effect of natalizumab on relapses in ... -
The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis.
Matesanz, Fuencisla; Fernández-Fernández, Óscar; Milne, Roger L.; Fedetz, María; Leyva-Fernández, Laura; Guerrero, Miguel; Delgado, Concepción; Lucas, Miguel; Izquierdo, Guillermo; Alcina, Antonio[et al.] (Elsevier, 2008)
Some polymorphisms in the FCRL3 gene, a member of the Fc-receptor like family, have been associated with several autoimmune diseases and recently with multiple sclerosis (MS). We performed a case–control study of three ...